ASCO 2024: SURE1 - Neoadjuvant Sacituzumab Govitecan in Urothelial Carcinoma

By The Uromigos - Last Updated: July 10, 2024

Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma from the new SURE1 trial.

Post Tags:Uromigos-ASCO

Advertisement

Related Podcasts

Episode 360: The SUNRISE Program in Bladder Cancer

Uromigos-Bladder Cancer

Episode 359: #UromigosLive24 - IO After IO in RCC

Uromigos Live 2024: Focus on Kidney Cancer

Episode 358: Tres Uramigas - News From Day 1 of #UromigosLive24 in Nashville

Uromigos-Bladder Cancer

Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer

Uromigos Live 2024: Focus on Bladder Cancer

Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC

Uromigos Live 2024: Focus on Kidney Cancer

Advertisement

Advertisement